Form 4: Celldex SVP Sells Shares Under 10b5-1 Plan

Celldex Therapeutics' SVP & General Counsel, Freddy A. Jimenez, sold 4,166 shares of common stock for $29.095 per share under a pre-arranged 10b5-1 plan.

Summary

• Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, Inc. (CLDX), reported a sale of common stock.
• The transaction involved the disposition of 4,166 shares of Celldex Therapeutics Common Stock.
• The shares were sold at a price of $29.095 per share.
• Following this transaction, Mr. Jimenez beneficially owns 30,796 shares of common stock.
• The transaction was executed on December 4, 2025, and was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: A neutral score is assigned because the insider sale was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It represents a planned liquidity event rather than a reaction to new company developments.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on immediate insider information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction is a routine disclosure for a publicly traded biotechnology company. It does not inherently reflect broader industry trends but rather an individual's portfolio management under a pre-arranged plan.

Comparison to Industry Standards

• This Form 4 filing is a standard regulatory disclosure for insider transactions and does not provide data for comparison to specific industry benchmarks or competitor results.
• The transaction itself, being a sale under a 10b5-1 plan, aligns with common practices for executive liquidity management.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but mitigated by the 10b5-1 plan.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Key Dates

Recommendation

The insider sale by the SVP & General Counsel, while a reduction in direct ownership, was executed under a pre-arranged Rule 10b5-1(c) plan. This indicates a planned liquidity event rather than a reaction to new material non-public information. Therefore, this specific transaction alone does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Celldex Therapeutics, CLDX, Insider Trading, Form 4, Stock Sale, Freddy A. Jimenez, 10b5-1 Plan, Biotechnology, Pharmaceuticals